Click Here for 5% Off Your First Aladdin Purchase!

Fulranumab (anti-NGF) - Primary antibody, specific to NGF, >95%, high purity, Human IgG2, INHIBITOR of Beta-nerve growth factor inhibitor

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Cynomolgus monkey,Human,Mouse
  • Isotype: Human IgG2
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175829
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175829-100μg
100μg
In stock
$69.90
Ab175829-1mg
1mg
In stock
$327.90
Ab175829-5mg
5mg
In stock
$807.90
Ab175829-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,287.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series
Accession#:P01138 Gene ID:4803 NGF

Basic Description

Product NameFulranumab (anti-NGF) - Primary antibody, specific to NGF, >95%, high purity, Human IgG2
SynonymsBeta nerve growth factor antibody; Beta NGF antibody; Beta-nerve growth factor antibody; Beta-NGF antibody; HSAN5 antibody; MGC161426 antibody; MGC161428 antibody; Nerve growth factor (beta polypeptide) antibody; Nerve growth factor antibody; Nerve growth
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityNGF
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionINHIBITOR of Beta-nerve growth factor inhibitor
Product Description

Fulranumab (anti-NGF) is a human IgG2 monoclonal antibody against nerve growth factor (NGF) and can be used for the research of pain.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

IsotypeHuman IgG2
Light Chain Typekappa
SDS-PAGE25.9 kDa (Light Chain) & 50.5 kDa (Heavy Chain), under reducing conditions; 167.6 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS902141-80-4

Images

Fulranumab (anti-NGF) (Ab175829) - SEC
The purity of Fulranumab (anti-NGF) (Ab175829) is more than 95% verified by HPLC.

Fulranumab (anti-NGF) (Ab175829) - ELISA
Immobilized huNGFB at 2.0 μg/mL can bind Fulranumab (anti-NGF) (Ab175829) with the EC₅₀ of 15.96 ng/mL.

Associated Targets

NGF Tchem Beta-nerve growth factor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0102646Certificate of AnalysisJan 30, 2024 Ab175829
ZJ24F0102645Certificate of AnalysisJan 30, 2024 Ab175829
ZJ24F0102644Certificate of AnalysisJan 30, 2024 Ab175829

Related Documents

References

1. Klein, R R, Jing, S Q SQ, Nanduri, V V, O'Rourke, E E and Barbacid, M M..  (1991)  The trk proto-oncogene encodes a receptor for nerve growth factor..  Cell,    (5):   [PMID:1849459]
2. Hallböök, F F, Ibáñez, C F CF and Persson, H H..  (1991)  Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary..  Neuron,      [PMID:2025430]
3. Borsani, G G and 7 more authors..  (1990)  cDNA sequence of human beta-NGF..  Nucleic acids research,    (11):   [PMID:2374737]
4. Ullrich, A A, Gray, A A, Berman, C C, Coussens, L L and Dull, T J TJ..  (1983)  Sequence homology of human and mouse beta-NGF subunit genes..  Cold Spring Harbor symposia on quantitative biology,      [PMID:6327169]
5. Ullrich, A A, Gray, A A, Berman, C C and Dull, T J TJ..  (1983)  Human beta-nerve growth factor gene sequence highly homologous to that of mouse..  Nature,    (30):   [PMID:6688123]
6. Tong, Y Y, Wang, H H and Chen, W W..  (1997)  [Cloning and sequencing of the gene for premature beta nerve growth factor]..  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology,      [PMID:10322959]
7. Culmsee, C C, Semkova, I I and Krieglstein, J J..  (1999)  NGF mediates the neuroprotective effect of the beta2-adrenoceptor agonist clenbuterol in vitro and in vivo: evidence from an NGF-antisense study..  Neurochemistry international,      [PMID:10403429]
8. Wiesmann, C C, Ultsch, M H MH, Bass, S H SH and de Vos, A M AM..  (1999)  Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor..  Nature,    (9):   [PMID:10490030]
9. Semkova, I I and Krieglstein, J J..  (1999)  Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors..  Brain research. Brain research reviews,      [PMID:10525174]
10. Puls, I I and 5 more authors..  (1999)  [Clenbuterol in amyotrophic lateral sclerosis. No indication for a positive effect]..  Der Nervenarzt,      [PMID:10637819]
11. Riaz, S S SS and Tomlinson, D R DR..  (1999)  Clenbuterol stimulates neurotrophic support in streptozotocin-diabetic rats..  Diabetes, obesity & metabolism,      [PMID:11221812]
12. Einarsdottir, Elisabet E and 8 more authors..  (2004)  A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception..  Human molecular genetics,    (15):   [PMID:14976160]
13. He, Xiao-Lin XL and Garcia, K Christopher KC..  (2004)  Structure of nerve growth factor complexed with the shared neurotrophin receptor p75..  Science (New York, N.Y.),    (7):   [PMID:15131306]
14. Wehrman, Tom T and 5 more authors..  (2007)  Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors..  Neuron,    (4):   [PMID:17196528]
15. Wijeyewickrema, Lakshmi C LC, Gardiner, Elizabeth E EE, Gladigau, Elsa L EL, Berndt, Michael C MC and Andrews, Robert K RK..  (2010)  Nerve growth factor inhibits metalloproteinase-disintegrins and blocks ectodomain shedding of platelet glycoprotein VI..  The Journal of biological chemistry,    (16):   [PMID:20164177]
16. Carvalho, Ofélia P OP and 8 more authors..  (2011)  A novel NGF mutation clarifies the molecular mechanism and extends the phenotypic spectrum of the HSAN5 neuropathy..  Journal of medical genetics,      [PMID:20978020]
17. Davidson, G L G and 20 more authors..  (2012)  Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort..  Journal of neurology,      [PMID:22302274]
18. Cao, Ziqin and 6 more authors..  (2020)  Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs..  Aging,    (3):   [PMID:33293475]
19. Cargill, M M and 17 more authors..  (1999)  Characterization of single-nucleotide polymorphisms in coding regions of human genes..  Nature genetics,      [PMID:10391209]

Solution Calculators